Trial To Test Effect of Aspirin on Progression of Kidney Disease in Diabetes Interview with:
Francesco Violi MD
Department of Internal Medicine and Medical Specialties e Sapienza University
Rome, Italy What is the background for this study? What are the main findings?

Response: The paper reports on the protocol of a trial where we will test the effect of aspirin on renal disease progression in diabetic patients. The study will start shortly and will be terminate next year. What should readers take away from your report?

Response: Diabetic patients are at increased risk of renal disease but there is no therapeutic approach to retard renal failure.

We have previously reported that aspirin is associated with delayed renal disease progression in atrial fibrillation patients and decided to assess if this effect can be detected also in diabetic patients. What recommendations do you have for future research as a result of this study?

Response: I hope to provide useful information for the treatment of diabetic patients at the end of the trial. Thank you for your contribution to the community.


Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicentre, double-blind, placebo-controlled, randomised trial. The LEDA (renaL disEase progression by aspirin in Diabetic pAtients) trial. Rationale and study design
Francesco Violi, Giovanni Targher, Annarita Vestri, Roberto Carnevale, Maurizio Averna, Alessio Farcomeni, Andrea Lenzi, Francesco Angelico, Francesco Cipollone, Daniele Pastori
American Heart Journal April 2017

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″]

Last Updated on April 20, 2017 by Marie Benz MD FAAD